Last reviewed · How we verify
Ofatumumab 700
At a glance
| Generic name | Ofatumumab 700 |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Ofatumumab as Primary Therapy of Chronic Graft Versus Host Disease (PHASE1, PHASE2)
- Ofatumumab Dose-finding in Relapsing Remitting Multiple Sclerosis (RRMS) Patients (PHASE2)
- HuMax-CD20 in Active Rheumatoid Arthritis, Phase I/II (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ofatumumab 700 CI brief — competitive landscape report
- Ofatumumab 700 updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI